Vivimed Labs is locked at upper circuit limit of Rs. 12.84, up by 0.61 points or 4.99% from its previous closing of Rs. 12.23 on the BSE.
The scrip opened at Rs. 12.84 and has touched a high and low of Rs. 12.84 and Rs. 12.84 respectively. So far shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 19.00 on 23-Sep-2019 and a 52 week low of Rs. 6.50 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 12.84 and Rs. 10.06 respectively. The current market cap of the company is Rs. 101.40 crore.
The promoters holding in the company stood at 32.79%, while Institutions and Non-Institutions held 3.56% and 63.53% respectively.
Vivimed Labs has received export order for supply of 'Favulous' tablets 200 mg (Favipiravir). Favulous tablets 200 mg (Favipiravir) is used for the treatment of mild to moderate cases of Covid-19. Favipiravir is the only oral antiviral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid19 disease. The initial Export order value is worth over Rs 100 Million. The company expects to receive further repeat orders during the Year.
The company is launching Favulous at an economical price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with company’s continuous efforts to support world's pandemic response. The company will work closely with the various governments and medical community to ensure availability of Favulous to patients across the world.
Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1814.30 |
| Dr. Reddys Lab | 1347.50 |
| Cipla | 1479.00 |
| Lupin | 2177.70 |
| Zydus Lifesciences | 975.10 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
